[go: up one dir, main page]

MX2022001604A - Anticuerpos anti bdca-2. - Google Patents

Anticuerpos anti bdca-2.

Info

Publication number
MX2022001604A
MX2022001604A MX2022001604A MX2022001604A MX2022001604A MX 2022001604 A MX2022001604 A MX 2022001604A MX 2022001604 A MX2022001604 A MX 2022001604A MX 2022001604 A MX2022001604 A MX 2022001604A MX 2022001604 A MX2022001604 A MX 2022001604A
Authority
MX
Mexico
Prior art keywords
bdca
antibodies
antigen binding
binding molecules
clec4c
Prior art date
Application number
MX2022001604A
Other languages
English (en)
Inventor
Steve Holmes
Original Assignee
Capella Bioscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1911188.9A external-priority patent/GB201911188D0/en
Priority claimed from GBGB2000814.0A external-priority patent/GB202000814D0/en
Application filed by Capella Bioscience Ltd filed Critical Capella Bioscience Ltd
Publication of MX2022001604A publication Critical patent/MX2022001604A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a moléculas de unión a antígenos, en particular anticuerpos, fragmentos y variantes de los mismos, que se unen a BDCA-2 (CLEC4C), y al uso de dichas moléculas de unión a antígeno en el tratamiento y/o la prevención de trastornos inflamatorios y trastornos inmunes como las enfermedades autoinmunes.
MX2022001604A 2019-08-05 2020-08-05 Anticuerpos anti bdca-2. MX2022001604A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1911188.9A GB201911188D0 (en) 2019-08-05 2019-08-05 Antigen binding molecules that bind BDCA-2
GBGB2000814.0A GB202000814D0 (en) 2020-01-20 2020-01-20 Antigen binding molecules that bind bdca-2
PCT/EP2020/072051 WO2021023793A1 (en) 2019-08-05 2020-08-05 Anti bdca-2 antibodies

Publications (1)

Publication Number Publication Date
MX2022001604A true MX2022001604A (es) 2022-07-19

Family

ID=72234804

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001604A MX2022001604A (es) 2019-08-05 2020-08-05 Anticuerpos anti bdca-2.

Country Status (11)

Country Link
US (1) US20220162322A1 (es)
EP (1) EP4010374A1 (es)
JP (1) JP2022544106A (es)
KR (1) KR20220083668A (es)
CN (2) CN114641497B9 (es)
AU (1) AU2020324542A1 (es)
BR (1) BR112022002142A2 (es)
CA (1) CA3147096A1 (es)
IL (1) IL290262A (es)
MX (1) MX2022001604A (es)
WO (1) WO2021023793A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024010118A1 (ko) * 2022-07-07 2024-01-11 주식회사 유틸렉스 항 bdca-2 항체 및 이의 용도
TW202509070A (zh) * 2023-05-10 2025-03-01 新加坡商創响私人有限公司 Bdca2-標靶抗體及其用途
CN119119267A (zh) * 2023-06-12 2024-12-13 三生国健药业（上海）股份有限公司 抗bdca2抗体
WO2025051083A1 (zh) * 2023-09-05 2025-03-13 上海宏成药业有限公司 抗bdca-2特异性抗体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2928923T3 (da) * 2012-12-10 2020-02-17 Biogen Ma Inc Antistoffer mod dendritisk celle-antigen 2 fra blod og anvendelser deraf
EP3088519A4 (en) * 2013-12-24 2017-09-13 Astellas Pharma Inc. Novel anti-human bdca-2 antibody
EP3606952A1 (en) * 2017-04-07 2020-02-12 Miltenyi Biotec GmbH POLYPEPTIDES WITH MUTANT HUMAN IgG4

Also Published As

Publication number Publication date
CN114641497B9 (zh) 2025-03-11
CN114641497B (zh) 2025-02-21
IL290262A (en) 2022-04-01
CA3147096A1 (en) 2021-02-11
BR112022002142A2 (pt) 2022-04-19
WO2021023793A1 (en) 2021-02-11
CN114641497A (zh) 2022-06-17
US20220162322A1 (en) 2022-05-26
EP4010374A1 (en) 2022-06-15
AU2020324542A1 (en) 2022-03-24
JP2022544106A (ja) 2022-10-17
KR20220083668A (ko) 2022-06-20
CN119823996A (zh) 2025-04-15

Similar Documents

Publication Publication Date Title
MX2022001604A (es) Anticuerpos anti bdca-2.
PH12019502755A1 (en) Antibodies that specifically bind pd-1 and methods of use
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
ZA201706740B (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
NZ751246A (en) Anti-tim-3 antibodies and use thereof
MX2018010948A (es) INMUNOGLOBULINAS DE ENLACE A TGFß1 Y USOS DE LAS MISMAS.
NZ774327A (en) Therapeutic antibodies and their uses
MX2023001791A (es) Anticuerpos dirigidos contra receptor de interleucina 36 (il-36r).
MD20140108A2 (ro) Anticorpi împotriva metaloproteinazei 9 matriciale
MA34004B1 (fr) Protéines de liaison à cd127
MD20140107A2 (ro) Anticorpi împotriva metaloproteinazei 9 din matrice
MX2021009275A (es) Moleculas de union especificas.
PH12020550025A1 (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
MX2021011040A (es) Anticuerpos dirigidos contra c5ar.
MX2020007555A (es) Anticuerpos potenciadores del factor h y usos de los mismos.
PH12020551805A1 (en) Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
PH12022550671A1 (en) Antigen binding proteins
MX2022005718A (es) Anticuerpos tmem219 y usos terapeuticos de los mismos.
MX2021011830A (es) Anticuerpo anti fgf23.
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
PH12018501674A1 (en) Anti-citrullinated hla polypeptide antibodies and uses thereof
MX2020008768A (es) Agentes anticuerpos anti-cd25.